Table 3.
Treatments and Disease characteristics in patients with local disease
| Characteristic | No. of patients | (%) |
|---|---|---|
| No. of patients | 356 | 100 |
| Tumor size | ||
| T1 | 48 | 13.5 |
| T2 | 161 | 45.2 |
| T3 | 71 | 19.9 |
| T4 | 76 | 21.3 |
| N Statut | ||
| N0 | 107 | 30.1 |
| N1 | 74 | 20.8 |
| N2 | 93 | 26.1 |
| N3 | 82 | 23 |
| HER 2 | ||
| HER 2 negative | 23 | 48.9 |
| HER 2 positive | 24 | 51.1 |
| TNM | ||
| Stage I | 30 | 8.4 |
| Stage II | 140 | 39.3 |
| Stage III | 186 | 52.2 |
| Surgery | ||
| Yes | 347 | 97.5 |
| No | 9 | 2.5 |
| Surgery type | ||
| Radical mastectomy | 265 | 76.8 |
| Concerving surgery | 80 | 23.2 |
| Radiotherapy | ||
| Yes | 290 | 81.5 |
| No | 66 | 18.5 |
| Neoadjuvante chemotherapy | ||
| Yes | 76 | 21.3 |
| No | 280 | 78.7 |
| Neoadjuvante chemotherapy type | ||
| Anthracycline | 69 | 90.8 |
| CMF | 5 | 6.6 |
| AC60/TAXANE | 2 | 2.6 |
| Histological response to neoadjuvante chemotherapy | ||
| Chevalier 1 | 2 | 2.6 |
| Chevalier 2 | 6 | 7.9 |
| Chevalier 3 | 38 | 50 |
| Chevalier 4 | 30 | 39.5 |
| Adjuvant chemotherapy | ||
| Yes | 311 | 87.4 |
| No | 45 | 12.6 |
| Adjuvant hormonotherapy | ||
| Yes | 232 | 64.6 |
| No | 124 | 35.4 |